The Curosurf story is a tale of success. To date, the drug has saved the lives of around one million premature babies worldwide. And the story is far from over. Despite being 73, Tore Curstedt returns to the lab every day - the lab where he has developed a new variant of a drug that is set to help many more babies in the future.
In 2020, Gesynta raised SEK 190 million in one of the year’s largest private biotech investments in the Nordic region. Now the company is one step closer to a new drug for systemic sclerosis. The future promises several innovative treatments for a number of inflammatory diseases, including cardiovascular disease and cancer.